In last trading session, TScan Therapeutics Inc. (NASDAQ:TCRX) saw 1.35 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $2.89 trading at $0.44 or 17.96% at ring of the bell on the day assigns it a market valuation of $149.64M. That closing price of TCRX’s stock is at a discount of -108.65% from its 52-week high price of $6.03 and is indicating a premium of 49.83% from its 52-week low price of $1.45. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 92270.0 shares which gives us an average trading volume of 121.67K if we extend that period to 3-months.
For TScan Therapeutics Inc. (TCRX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.45 in the current quarter.
TScan Therapeutics Inc. (NASDAQ:TCRX) trade information
Upright in the green during last session for gaining 17.96%, in the last five days TCRX remained trading in the green while hitting it’s week-highest on Friday, 09/15/23 when the stock touched $2.89 price level, adding 1.37% to its value on the day. TScan Therapeutics Inc.’s shares saw a change of 86.45% in year-to-date performance and have moved 19.92% in past 5-day. TScan Therapeutics Inc. (NASDAQ:TCRX) showed a performance of 37.62% in past 30-days. Number of shares sold short was 0.35 million shares which calculate 4.87 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $10.75 to the stock, which implies a rise of 73.12% to its current value. Analysts have been projecting $6.00 as a low price target for the stock while placing it at a high target of $15.00. It follows that stock’s current price would drop -419.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of -107.61% for stock’s current value.
TScan Therapeutics Inc. (TCRX) estimates and forecasts
Statistics highlight that TScan Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 10.31% of value to its shares in past 6 months, showing an annual growth rate of 34.55% while that of industry is 12.00. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 32.80% in the current quarter and calculating 56.40% increase in the next quarter. This year revenue growth is estimated to rise 76.50% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $4.09 million for the same. And 4 analysts are in estimates of company making revenue of $11.91 million in the next quarter that will end on Dec 2023. Company posted $3.7 million and $3.1 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 10.50% while estimating it to be 284.70% for the next quarter.
TScan Therapeutics Inc. is more likely to be releasing its next quarterly report in October and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
TScan Therapeutics Inc. (NASDAQ:TCRX)’s Major holders
Insiders are in possession of 3.24% of company’s total shares while institution are holding 69.68 percent of that, with stock having share float percentage of 72.01%. Investors also watch the number of corporate investors in a company very closely, which is 69.68% institutions for TScan Therapeutics Inc. that are currently holding shares of the company. Lynx1 Capital Management Lp is the top institutional holder at TCRX for having 5.22 million shares of worth $13.06 million. And as of Jun 29, 2023, it was holding 12.00% of the company’s outstanding shares.
The second largest institutional holder is EcoR1 Capital, LLC, which was holding about 5.0 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 11.48% of outstanding shares, having a total worth of $12.5 million.
On the other hand, BlackRock Health Sciences Term Trust and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.2 million shares of worth $3.01 million or 2.77% of the total outstanding shares. The later fund manager was in possession of 1.19 million shares on Jun 29, 2023, making its stake of worth around $2.98 million in the company or a holder of 2.74% of company’s stock.